Published in Dig Dis Sci on August 25, 2009
5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis. PLoS One (2014) 0.87
Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol (2012) 0.86
Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-analysis. PLoS One (2013) 0.83
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. Clin Pharmacol (2012) 0.82
Chemoprevention of gastrointestinal cancer: the reality and the dream. Gut Liver (2013) 0.81
Hyperhomocysteinemia as a potential contributor of colorectal cancer development in inflammatory bowel diseases: a review. World J Gastroenterol (2015) 0.80
Chemopreventive effects of 5-amino salicylic acids on inflammatory bowel disease-associated colonic cancer and colonic dysplasia: a meta-analysis. Int J Clin Exp Med (2015) 0.77
Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis. Oncotarget (2016) 0.75
Cysteinyl leukotriene receptor 1 facilitates tumorigenesis in a mouse model of colitis-associated colon cancer. Oncotarget (2017) 0.75
Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease? World J Gastroenterol (2016) 0.75
The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut (2001) 10.07
Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet (2007) 7.81
Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med (1990) 6.87
Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer (2001) 4.61
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology (2004) 4.45
Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol (2004) 3.63
The use of electronic medical records: communication patterns in outpatient encounters. J Am Med Inform Assoc (2001) 3.29
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol (2005) 2.98
Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol (2003) 2.39
Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther (2000) 2.25
Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol (2006) 1.76
Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology (2001) 1.63
Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol (1996) 1.41
5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut (2005) 1.29
The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology (1997) 1.19
5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis (2007) 1.14
Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis (2008) 1.09
Relevance of folate metabolism in the pathogenesis of colorectal cancer. J Lab Clin Med (2001) 1.05
5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis. Inflamm Bowel Dis (2008) 1.03
Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. Am J Gastroenterol (2003) 0.99
Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am (2006) 0.91
5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. World J Gastroenterol (2005) 0.90
Chemoprevention of colorectal cancer in ulcerative colitis. Int J Colorectal Dis (2003) 0.85
Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete? World J Gastroenterol (2006) 0.82
Effects of dietary folate on ulcerative colitis-associated colorectal carcinogenesis in the interleukin 2- and beta(2)-microglobulin-deficient mice. Cancer Epidemiol Biomarkers Prev (2003) 0.79
CD14 is a coreceptor of Toll-like receptors 7 and 9. J Exp Med (2010) 1.64
Lipocalin 2 deactivates macrophages and worsens pneumococcal pneumonia outcomes. J Clin Invest (2013) 1.32
The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center [corrected]. J Clin Gastroenterol (2005) 1.18
TREM-1 activation alters the dynamics of pulmonary IRAK-M expression in vivo and improves host defense during pneumococcal pneumonia. J Immunol (2009) 1.16
TLR 2 and CD14 mediate innate immunity and lung inflammation to staphylococcal Panton-Valentine leukocidin in vivo. J Immunol (2010) 1.07
Examining warfarin underutilization rates in patients with atrial fibrillation: Detailed chart review essential to capture contraindications to warfarin therapy. Thromb J (2008) 1.03
Internalization and coreceptor expression are critical for TLR2-mediated recognition of lipoteichoic acid in human peripheral blood. J Immunol (2010) 0.95
Oral broccoli sprouts for the treatment of Helicobacter pylori infection: a preliminary report. Dig Dis Sci (2004) 0.91
The protein tyrosine kinase Tec regulates a CD44highCD62L- Th17 subset. J Immunol (2010) 0.90
Tyrosine kinase 2 controls IL-1ß production at the translational level. J Immunol (2010) 0.88
Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States. J Hepatol (2012) 0.84
WAVE1 mediates suppression of phagocytosis by phospholipid-derived DAMPs. J Clin Invest (2013) 0.81
Urinary stone composition in Oman: with high incidence of cystinuria. Urolithiasis (2015) 0.79
Lubiprostone plus PEG electrolytes versus placebo plus PEG electrolytes for outpatient colonoscopy preparation: a randomized, double-blind placebo-controlled trial. Am J Ther (2015) 0.76
An Evaluation of Provincial Infectious Disease Surveillance Reports in Ontario. J Public Health Manag Pract (2017) 0.75
Post-bloodmeal diuretic shedding of hepatitis B virus by mosquitoes (Diptera: Culicidae). J Med Entomol (2002) 0.75
Golimumab may induce exacerbation of inflammatory bowel disease when it is used for the treatment of ankylosing spondylitis: a case report with a review of literature. Am J Ther (2014) 0.75
Accumulating evidence for a role of oxidized phospholipids in infectious diseases. Cell Mol Life Sci (2014) 0.75